How big is Spruce Biosciences, Inc.?

As of Jun 18, Spruce Biosciences, Inc. has a market capitalization of 3.07 million, with net sales of 2.91 million and a net profit of -55.45 million over the last four quarters. The company reported shareholder's funds of 28.82 million and total assets of 45.21 million as of Dec 24.

Market Cap: As of Jun 18, Spruce Biosciences, Inc. has a market capitalization of 3.07 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Spruce Biosciences reported net sales of 2.91 million and a net profit of -55.45 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 28.82 million and total assets of 45.21 million.

What does Spruce Biosciences, Inc. do?

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing therapies for endocrine disorders, particularly congenital adrenal hyperplasia (CAH). It has a market cap of $3.07 million and reported a net profit loss of $14 million as of March 2025.

Overview: <BR>Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for endocrine disorders, specifically targeting congenital adrenal hyperplasia (CAH). It operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3.07 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.56 <BR>Return on Equity: -361.86% <BR>Price to Book: 0.20<BR><BR>Contact Details: <BR>Address: 2001 Junipero Serra Blvd., Suite 640, DALY CITY CA: 94104-5401 <BR>Tel: 1 302 6365400 <BR>Fax: 1 302 6365454 <BR>Website: http://www.sprucebiosciences.com/

Should I buy, sell or hold Spruce Biosciences, Inc.?

Who are in the management team of Spruce Biosciences, Inc.?

As of March 2022, the management team of Spruce Biosciences, Inc. includes Mr. Michael Grey (Chairman of the Board), Mr. Richard King (CEO and Director), and Dr. Niall O'Donnell (Director).

As of March 2022, the management team of Spruce Biosciences, Inc. includes Mr. Michael Grey, who serves as the Chairman of the Board, and Mr. Richard King, who is the Chief Executive Officer and a Director. Additionally, Dr. Niall O'donnell is also a Director on the board.

Is Spruce Biosciences, Inc. overvalued or undervalued?

As of May 15, 2023, Spruce Biosciences, Inc. is considered risky and overvalued due to its low Price to Book Value of 0.18, an EV to EBITDA ratio of 0.37, and significant underperformance with a stock return of -73.54% over the past year, despite a high ROCE of 670.25% and a concerning negative ROE of -361.86%.

As of 15 May 2023, the valuation grade for Spruce Biosciences, Inc. has moved from does not qualify to risky, indicating increased uncertainty regarding its valuation. The company appears to be overvalued, particularly given its low Price to Book Value of 0.18 and an EV to EBITDA ratio of 0.37, which suggests that investors are paying a premium relative to its earnings potential. Additionally, the ROCE stands at an impressive 670.25%, yet the negative ROE of -361.86% raises concerns about profitability and financial health.<BR><BR>In comparison to its peers, Spruce Biosciences has a P/E ratio that is not applicable due to its loss-making status, while CARA Therapeutics, Inc. has a P/E of -9.4978 and NGM Biopharmaceuticals, Inc. shows a P/E of -0.9351, highlighting the challenging environment for these companies. Over the past year, Spruce Biosciences has significantly underperformed, with a stock return of -73.54% compared to a 17.14% return for the S&P 500, reinforcing the notion that the stock may be overvalued in the current market context.

Is Spruce Biosciences, Inc. technically bullish or bearish?

As of September 5, 2025, Spruce Biosciences, Inc. shows a bullish trend despite short-term bearish signals, with year-to-date and one-year returns significantly underperforming the S&P 500.

As of 5 September 2025, the technical trend for Spruce Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view including a bullish monthly RSI and a bullish weekly KST. However, the daily moving averages indicate a mildly bearish trend, which suggests some short-term weakness. <BR><BR>In terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.8% versus the S&P's 12.22%, and a one-year return of -73.54% compared to the S&P's 17.14%.